Current management in polycythemia vera.

@article{Gilbert2001CurrentMI,
  title={Current management in polycythemia vera.},
  author={Harriet S. Gilbert},
  journal={Seminars in hematology},
  year={2001},
  volume={38 1 Suppl 2},
  pages={25-8}
}
Myeloproliferative diseases (MPD) include polycythemia vera (PV), essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia. The focus of this report is on PV, which is characterized by an increase in red blood cells, granulocytes, and platelets. Complications associated with PV are an increased risk of thrombosis and abnormal bleeding. Phlebotomy to a hematocrit less than 45% is the mainstay of treatment for erythrocythemia, but may further increase the platelet… CONTINUE READING

Similar Papers

Loading similar papers…